Idorsia Transfers its Agreement with ReveraGen to Santhera for Vamorolone

 Idorsia Transfers its Agreement with ReveraGen to Santhera for Vamorolone

https://pharmashots.com/press-releases/idorsia-assigns-and-transfers-agreement-with-reveragen-to-santhera/

Shots:

  • Idorsia transfers its development & commercialization agreement with ReveraGen to Santhera, whereby Santhera shall replace Idorsia as a party to the agreement.  Santhera to get an exclusive license, including sublicensing rights, for vamorolone in all indications globally, including Japan and South Korea and a share in expected PR voucher
  • In exchange for the revised license rights, Idorsia will receive 366,667 Santhera’s shares and an exchangeable note of $10.9M and is eligible to receive development & commercial milestones on sales of therapy. ReveraGen will receive $7M, in monthly installments of up to $500,000, to fund the ongoing clinical development of vamorolone
  • Santhera exercises the option to get global rights to vamorolone in DMD and all other indications. ReveraGen is evaluating Vamorolone in P-IIb VISION-DMD study and expects the completion of enrollment shortly

Click here, Click Here ­to­ read full press release/ article | Ref: PRNewswire | Image: Santhera

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post